Cancer Research 2010 AACR Elections 2010 Workshops
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hemminki, A.
Right arrow Articles by Curiel, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hemminki, A.
Right arrow Articles by Curiel, D. T.
[Cancer Research 61, 6377-6381, September 1, 2001]
© 2001 American Association for Cancer Research

Advances in Brief

Targeting Oncolytic Adenoviral Agents to the Epidermal Growth Factor Pathway with a Secretory Fusion Molecule1

Akseli Hemminki2, Igor Dmitriev, Bin Liu, Renee A. Desmond, Ramon Alemany and David T. Curiel

Division of Human Gene Therapy, Departments of Medicine, Pathology, and Surgery, and the Gene Therapy Center [A. H., I. D., B. L., R. A., D. T. C.], and Comprehensive Cancer Center Biostatistics Unit [R. A. D.], University of Alabama at Birmingham, Birmingham, Alabama 35294-3300

Cancer gene therapy with conditionally replicating adenoviruses is a powerfulway of overcoming low tumor transduction. However, one of the main remaining obstacles is the highly variable level of the coxsackie-adenovirus receptor expression on human primary cancers. In contrast, the epidermal growth factor receptor (EGFR) is overexpressed in various tumor types, and its expression correlates with metastatic behavior and poor prognosis. We constructed an adenovirus expressing a secretory adaptor capable of retargeting adenovirus to EGFR, resulting in a more than 150-fold increase in gene transfer. A replication-competent dual-virus system secreting the adaptor displayed increased oncolytic potency in vitro and therapeutic gain in vivo. This approach could translate into increased efficacy and specificity in the treatment of EGFR overexpressing human cancers.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
K. Guse, T. Ranki, M. Ala-Opas, P. Bono, M. Sarkioja, M. Rajecki, A. Kanerva, T. Hakkarainen, and A. Hemminki
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses
Mol. Cancer Ther., October 1, 2007; 6(10): 2728 - 2736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Tsuruta, L. Pereboeva, J. N. Glasgow, D. T. Rein, Y. Kawakami, R. D. Alvarez, R. P. Rocconi, G. P. Siegal, P. Dent, P. B. Fisher, et al.
A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus {sigma}1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor Independent Pathway
Clin. Cancer Res., May 1, 2007; 13(9): 2777 - 2783.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Rajecki, A. Kanerva, U.-H. Stenman, M. Tenhunen, L. Kangasniemi, M. Sarkioja, M. Y. Ala-Opas, H. Alfthan, A. Sankila, E. Rintala, et al.
Treatment of prostate cancer with Ad5/3{Delta}24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo
Mol. Cancer Ther., February 1, 2007; 6(2): 742 - 751.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Kangasniemi, T. Kiviluoto, A. Kanerva, M. Raki, T. Ranki, M. Sarkioja, H. Wu, F. Marini, K. Hockerstedt, H. Isoniemi, et al.
Infectivity-Enhanced Adenoviruses Deliver Efficacy in Clinical Samples and Orthotopic Models of Disseminated Gastric Cancer.
Clin. Cancer Res., May 15, 2006; 12(10): 3137 - 3144.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
F. Kuhnel, B. Schulte, T. Wirth, N. Woller, S. Schafers, L. Zender, M. Manns, and S. Kubicka
Protein Transduction Domains Fused to Virus Receptors Improve Cellular Virus Uptake and Enhance Oncolysis by Tumor-Specific Replicating Vectors
J. Virol., December 15, 2004; 78(24): 13743 - 13754.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hakkarainen, A. Hemminki, A. V. Pereboev, S. D. Barker, C. K. Asiedu, T. V. Strong, A. Kanerva, J. Wahlfors, and D. T. Curiel
CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses
Clin. Cancer Res., February 1, 2003; 9(2): 619 - 624.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. J. Bauerschmitz, J. T. Lam, A. Kanerva, K. Suzuki, D. M. Nettelbeck, I. Dmitriev, V. Krasnykh, G. V. Mikheeva, M. N. Barnes, R. D. Alvarez, et al.
Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus
Cancer Res., March 1, 2002; 62(5): 1266 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. M. Shayakhmetov, Z.-Y. Li, S. Ni, and A. Lieber
Targeting of Adenovirus Vectors to Tumor Cells Does Not Enable Efficient Transduction of Breast Cancer Metastases
Cancer Res., February 1, 2002; 62(4): 1063 - 1068.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.